A Phase 3, 2-Part, Open-Label and Double-Blind, Randomised Study to Evaluate the Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis
Active, not recruitingCTIS2023-508235-31-00
Almirall S.A.Atopic Dermatitis
Start: 2024-06-17Target: 522Updated: 2026-01-07